Hansa says small trial shows its investigational drug could expand use of Sarepta’s Elevidys

Hansa Biopharma said data from a handful of Duchenne patients suggest its drug candidate could open the door for more people to be treated with Sarepta’s gene therapy Elevidys. In an open-label trial, three boys ...